Menu
Not yet recruiting NCT06692231

Impact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients

No phase Interventional Renal Dialysis Health Literacy Level Kidney Disease, Chronic

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Pharmacist intervention.
Who it may be relevant to
Registry conditions: Renal Dialysis, Health Literacy Level, Kidney Disease, Chronic. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Impact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients After Assessment of Health Literacy Level

Overview

The goal of this clinical trial is to learn if an intervention of a hospital pharmacist could help, dialysis patients managed his treatment. In a first time, the health literacy level will be assed. The main questions it aims to answer are: What is the impact of the clinical pharmacist intervention on the understanding level and management level of his treatment by the patient? Does the intervention of the pharmacist has an effect on the biologicals parameters of the patient? Researchers will compare a group with a pharmacist intervention VS a group without pharmacist intervention for dialysis patients.

Interventions

  • Behavioral Pharmacist intervention
    Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.

Primary outcome measures

  • Level of understanding and treatment management [Time frame: 12 months]
Secondary outcome measures (9)
  • level of health literacy [Time frame: 12 months]
  • Assessment of patient-reported compliance with medication [Time frame: 12 months]
  • Kalemia evolution [Time frame: 12 months]
  • Phosphatemia evolution [Time frame: 12 months]
  • Calcemia evolution [Time frame: 12 months]
  • PTH evolution [Time frame: 12 months]
  • Vitamine D evolution [Time frame: 12 months]
  • Quality of life [Time frame: 12 months]
  • Assessment of compliance with medication [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • Patient over 18 years of age
  • On dialysis (peritoneal dialysis, hemodialysis) for at least 3 months
  • Prescription for at least 5 daily medications
  • Patient who has not received any pharmaceutical consultation from a hospital pharmacist as part of his or her treatment for chronic renal failure.

Exclusion criteria

  • Patient does not speak and/or understand French
  • Patient's cognitive state does not permit an interview
  • Patient not autonomous in managing his or her daily medication (e.g.: patient in nursing home)
  • Patient refusal

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

France · 1 center
  • Centre hospitalier de Vichy — Vichy

Identifiers

NCT: NCT06692231 · CHV-2024-10

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗